Bausch & Lomb announced an agreement with Novartis to acquire dry eye drug Xiidra (along with a few early-stage eye care products) for $1.75 billion in upfront cash and potential sales-based milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results